FIELD: medicine.
SUBSTANCE: chimeric polypeptide contains a first domain which is a first intracellular loop (i1-loop) of chemokine receptor, and a second domain coupled with the first domain where the second domain is a cell-penetrating and membrane-bound natural or artificial hydrophobic residue. The produced polypeptide is used in treating a disease or a condition characterised by pathological activity of chemokine receptor.
EFFECT: invention enables producing chimeric polypeptide which is selectively reacting with related chemokine receptor.
13 cl, 33 dwg, 3 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHOTOSENSITIVE CHIMERIC PROTEIN GPCR | 2012 |
|
RU2637367C2 |
| COMPOSITIONS AND METHODS RELATED TO SOLUBLE G-PROTEIN CONJUGATE RECEPTORS (SGPCR) | 2006 |
|
RU2423378C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2684713C2 |
| CHIMERIC ANTIGENIC RECEPTORS TO CD22 | 2012 |
|
RU2644243C2 |
| CHIMERIC ANTIGENIC RECEPTOR | 2015 |
|
RU2685479C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| M971 CHIMERIC ANTIGEN RECEPTORS | 2013 |
|
RU2658485C2 |
| POLYPEPTIDES FOR TREATING STRESS SYNDROMES, IMMUNE RESPONSE AND STROKE | 2019 |
|
RU2824567C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
